Exploring the interaction between technology and morality in the field of genetic susceptibility testing: A scenario study

Futures

Volumn 42, Issue 10, 2010, Pages 1133-1145

  Stemerding, Dirk ^a   Swierstra, Tsjalling ^a   Boenink, Marianne ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Genetics; Morality; Scenario; Screening; Technology

Indexed keywords

BIOTECHNOLOGY; DETECTION METHOD; FUTURE PROSPECT; GENOMICS; MORALITY; PUBLIC HEALTH; TECHNOLOGICAL DEVELOPMENT;

EID: 77956388230     PISSN: 00163287     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.futures.2009.12.001     Document Type: Article

References (106)

1. Davison C., Macintyre S., Davey Smith G. The potential social impact of predictive genetic testing for susceptiblity to common chronic diseases: a review and proposed research agenda. Sociology of Health and Illness 1994, 16(3):340-371.
2. Bourret P., Koch L., Stemerding D. DNA diagnosis and the emergence of cancer genetic services in European health care. The Social Management of Genetic Engineering 1998, 117-138. Ashgate, London. P. Wheale, R. von Schomberg, P. Glasner (Eds.).
3. Umans-Eckenhausen M.A., Defesche J.C., Sijbrands E.J., Scheerder R.L., Kastelein J.J. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001, 357:165-168.
4. Horstman K. Lifestyle, genes and cholesterol: new struggles about responsibility and solidarity. Genetics from Laboratory to Society: Societal Learning as an Alternative to Regulation 2008, 64-89. Palgrave Macmillan, Basingstoke. G.H. de Vries, K. Horstman (Eds.).
5. Collins F.S. The human genome project and the future of medicine. Annals of the New York Academy of Science 1999, 882:42-55.
6. Kaufert P.A. Health policy and new genetics. Social Science and Medicine 2000, 51:821-829.
7. Genetics and Public Health in the 21st Century. Using Genetic Information to Improve Health and Prevent Disease 2000, Oxford University Press, Oxford. M.J. Khoury, W. Burke, E.J. Thomson (Eds.).
8. Zimmern R., Cook C. Genetics and Health, Policy Issues for Genetic Science and their Implications for Health and Health Services 2000, Nuffield Trust, London.
9. Halliday J.L., Collins R., Aitken M.A., Richards M.P.M., Olsson C.A. Genetics and public health-evolution or revolution?. Journal of Epidemiology and Community Health 2004, 58:894-899.
10. Calnan M., Wainwight D., Glasner P., Newbury-Ecob R., Ferlie E. 'Medicine's next goldmine?' The implication of new genetic health technologies for the health service. Medicine, Health Care and Philosophy 2006, 9:33-41.
11. Brand A., Brand H. Public health genomics-relevance of genomics for individual health information management, health policy development and effective health services. Italian Journal of Public Health 2006, 3(3-4):24-34.
12. Gwinn M., Khoury M.J. Genomics and public health in the United States: signposts on the translation highway. Community Genetics 2006, 9:21-26.
13. Zimmern R., Stewart A. Public health genomics: origins and basic concepts. Italian Journal of Public Health 2006, 3(3-4):9-15.
14. Smith K. Genetic testing of the general population: ethical and informatic concerns. Critical Reviews in Biomedical Engineering 2000, 28(4-5):557-561.
15. Danish Council of Ethics Genetic Investigation of Healthy Subjects, Report on Presymptomatic Genetic Testing 2002, Danish Council of Ethics, Copenhagen.
16. Merikangas K., Risch N. Genomic Priorities and Public Health. Science 2003, 302:599-601.
17. Davey Smith G., Ebrahim S., Lewis S., Hansell A.L., Palmer L.J., Burton P.R. Genetic epidemiology and public health: hope, hype, and future prospects. Lancet 2005, 366:1484-1498.
18. Grosse S.D., Khoury M.J. What is the clinical utility of genetic testing?. Genetics in Medicine 2006, 8(7):448-450.
19. Holtzman N.A. What role for public health in genetics and vice versa?. Community Genetics 2006, 9:8-20.
20. Martin P., Morrison M. Realising the Potential of Genomic Medicine 2006, Institute for the Study of Genetics, Biorisks and Society, University of Nottingham.
21. Schröder P. Why genomics will not revolutionise public health. Italian Journal of Public Health 2006, 3(3-4):16-19.
22. Farmer Y., Godard B. Public health genomics (PHG): from scientific considerations to ethical integration. Genomics, Society and Policy 2007, 3(3):14-27.
23. Hunter D.J., Khoury M.J., Drazen J.M. Letting the genome out of the bottle-will we get our wish?. New England Journal of Medicine 2008, 358(2):105-107.
24. Swierstra T.E., Stemerding D., Boenink M. Exploring techno-moral change. The case of the obesity pill. Evaluating New Technologies. Methodological Problems for the Ethical Assessment of Technology Developments 2009, 119-138. Springer, Berlin. P. Sollie, M. Düwel (Eds.).
25. M. Boenink, T.E. Swierstra, D. Stemerding, Anticipating the interaction between technology and morality: a techno-ethical scenario study of experimenting with humans in bionanotechnology. Studies in Ethics, Law en Technology, forthcoming (2010).
26. Swierstra T.E., Rip A. NEST-ethics: patterns of moral argumentation about new and emerging science and technology. Nanoethics 2007, 1:3-20.
27. Valone D.A. The changing moral landscape of human reproduction: two moments in the history of in vitro fertilization. The Mount Sinai Journal of Medicine 1998, 65(9):167-172.
28. Svendsen M.N., Koch L. Unpacking the 'spare embryo': facilitating stem cell research in a moral landscape. Social Studies of Science 2008, 38(1):93-110.
29. Godard B., ten Kate L., Evers-Kiebooms G., Aymé S. Population genetic screening programmes: principles, practices and policies. European Journal of Human Genetics 2003, 11(Suppl. 2):S49-87.
30. Khoury M.J., McCabe L.L., McCabe E.R.B. Population screening in the age of genomic medicine. New England Journal of Medicine 2003, 348(1):50-58.
31. Caulfield T., Wertz D. Creating needs? A review of survey data and concerns relevant to the commercialization of genetic testing. Community Genetics 1999, 4(2):568-576.
32. Rip A., Kemp R. Technological change. Human Choice and Climate Change 1998, 327-399. Batelle Press, Columbus. S. Rayner, E.L. Malone (Eds.).
33. Moors E.H.M., Rip A., Wiskerke J.S.C. The dynamics of innovation: a multilevel co-evolutionary perspective. Seeds of Transition. Essays on Novelty Production, Niches and Regimes in Agriculture 2004, 31-56. Van Gorcum, Assen. J.S.C. Wiskerke, J.D. van der Ploeg (Eds.).
34. Stemerding D., Swierstra T.E. How might scenariostudies help us to think about the normative implications of genomics and predictive medicine?. Question éthiques en médicine predictive 2006, 81-88. John Libbey Eurotext, Paris. A. de Bouvet, P. Boitte, G. Aiguier (Eds.).
35. Luján J.L., Moreno L. Biological lottery and social solidarity. The impacts of genetic diagnosis. Futures 1996, 28(5):497-500.
36. M. Boenink, Mammographic breast cancer screening in the Netherlands: mapping potential and actual moral debate, Working paper, University of Twente, Enschede, 2007.
37. Wilson J.M.G., Jungner G. Principles and Practice of Screening for Disease 1968, World Health Organization, Geneva.
38. The Health Council of the Netherlands, Annual Report on Screening for Disease, The Hague, 2006.
39. Haddow J., Palomaki G. AAC: a model for evaluating data on emerging genetic tests. Human Genome Epidemiology. A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease 2004, 217-233. Oxford University Press, Oxford. M.J. Khoury, J. Little, W. Burke (Eds.).
40. British Medical Association Population Screening and Genetic Testing. A Briefing of Current Programmes and Technologies 2005, British Medical Association, London.
41. Nuffield Council on Bioethics Genetic Screening, Ethical Issues 1993, Nuffield Council on Bioethics, London.
42. Nuffield Council on Bioethics Genetic Screening, a Supplement to the 1993 Report 2006, Nuffield Council on Bioethics, London.
43. The Health Council of the Netherlands Screening between Hope and Hype 2008, The Health Council of the Netherlands, The Hague.
44. The Health Council of the Netherlands Genetic Screening 1994, The Health Council of the Netherlands, The Hague.
45. Hoedemaekers R., ten Have H., Chadwick R.F. Genetic screening: a comparative analysis of three recent reports. Journal of Medical Ethics 1997, 23:135-141.
46. Caulfield T. Regulating the commercialization of human genetics. Can we address the big concerns?. Genetic Information. Acquisition, Access, and Control 1999, 149-161. Kluwer, New York. A.K. Thomson, R.F. Chadwick (Eds.).
47. Levitt M. Let the consumer decide? The regulation of commercial testing. Journal of Medical Ethics 2001, 27:398-403.
48. Martin P., Frost R. Regulating the commercial development of genetic testing in the UK: problems, possibilities and policy. Critical Social Policy 2003, 23(2):186-207.
49. Bowen D.J., Batuello K.M., Raats M. Marketing genetic tests: empowerment or snake oil?. Health Education and Behavior 2005, 32(5):676-685.
50. Williams-Jones B. 'Be ready against cancer now': direct-to-consumer advertising for genetic testing. New Genetics and Society 2006, 25(1):89-108.
51. Hoedemaekers R. Commercial predictive testing: the desirability of one overseeing body. Journal of Medical Ethics 2006, 26:282-286.
52. The Health Council of the Netherlands Annual Report on Screening for Disease-the Self-testing of Body Samples 2007, The Health Council of the Netherlands, The Hague.
53. Janssens A.C., Gwinn M., Bradley L.A., Oostra B.A., van Duijn C.M., Khoury M.J. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalized health interventions. American Journal of Human genetics 2008, 82:593-599.
54. van den Daele W. The spectre of coercion: is public health genetics the route to policies of enforced disease prevention?. Community Genetics 2006, 9(1):40-49.
55. Bayer R., Fairchild A.M. The genesis of public health ethics. Bioethics 2004, 18(6):473-492.
56. Mooij A. Geen paniek! Aids in Nederland 1982-2004 2004, Bert Bakker, Amsterdam.
57. Ministry of Health Langer Gezond Leven; Ook een Kwestie van Gezond Gedrag 2003, Ministry of Health, The Hague.
58. Ministry of Health Kiezen voor Gezond Leven 2006, Ministry of Health, The Hague.
59. Council for Public Health and Health Care Het Preventieconcert (The Prevention Concert) 2005, Council for Public Health and Health Care, Zoetermeer.
60. Council for Public Health and Health Care Publieke Gezondheid (Public Health) 2006, Council for Public Health and Health Care, Zoetermeer.
61. National Institute for Public Health, Environment Public Health Forecast 2006, National Institute for Public Health and Environment, Bilthoven.
62. Petersen A., Bunton R. The New Genetics and the Public Health 2002, Routledge, London.
63. Horstman K., Houtepen H. Worstelen met Gezond Leven. Ethiek in de Preventie van Hart- en Vaatziekten 2005, Het Spinhuis, Amsterdam.
64. Council for Public Health and Health Care RVZ Briefadvies Houdbare Solidariteit in de Gezondheidszorg (Tenable Solidarity in the Health Care System) 2006, Council for Public Health and Health Care RVZ, Zoetermeer.
65. Royal Netherlands Academy of Arts and Sciences Multifactoriële aandoeningen in het genomics-tijdperk 2006, Royal Netherlands Academy of Arts and Sciences, Amsterdam.
66. American Diabetes Association Screening for diabetes. Diabetes Care 2002, 52(Suppl. 1):S21-S24.
67. The Health Council of the Netherlands Screening for Type 2 Diabetes 2004, The Health Council of the Netherlands, The Hague.
68. Bharadwaj A., Prior L., Atkinson P., Clarke A., Worwood M. The genetic iceberg: risk and uncertainty. New Technologies in Health Care. Challenge, Change and Innovation 2006, 11-24. Palgrave Macmillan, Basingstoke. A. Webster (Ed.).
69. Burke W., Psaty B.M. Personalized medicine in the era of genomics. JAMA 2007, 298(14):1682-1684.
70. Engelgau M.M., Narayan V.K.M., Herman W.H. Screening for type 2 diabetes. Diabetes Care 2000, 23(10):1563-1580.
71. Gooding H.C., Organista K., Burack J., Bowles Biesecker B. Genetic susceptibility testing from a stress and coping perspective. Social Science and Medicine 2006, 62:1880-1890.
72. Haga S.B., Khoury M.J., Burke W. Genomic profiling to promote a healthy lifestyle: not ready for prime time. Nature Genetics 2003, 34(4):347-350.
73. Hedgecoe A. Reinventing diabetes: classification, division and the geneticization of disease. New Genetics and Society 2002, 21(1):7-27.
74. Janssens A.C., Aulchenko Y.S., Elefante S., Borsboom G.J.J.M., Steyerberg E.W., van Duyn C.M. Predictive testing for complex diseases using multiple genes: fact or fiction?. Genetics in Medicine 2006, 8(7):395-400.
75. Janssens A.C., Khoury M.J. Predictive value of testing for multiple genetic variants in multifactorial diseases: implications for the discourse on ethical, legal and social issues. Italian Journal of Public Health 2006, 3(3-4):35-41.
76. Beck-Gernsheim E. Health and responsibility: from social change to technological change and vice versa. The Risk Society and Beyond. Critical Issues for Social Theory 2000, 122-135. Sage, London. B. Adam, U. Beck, J. van Loon (Eds.).
77. Finkler K., Skrzybnia C., Evans J. The new genetics and its consequences for family, kinship, medicine and medical genetics. Social Science and Medicine 2003, 57:403-412.
78. Gustafsson-Stolt U., Liss P.E., Ludvigsson J. Parents want to know if their child is at high risk of getting diabetes. Annals New York Academy of Science 2003, 1005:395-399.
79. Kardia S.L., Wang C. The role of health education and behavior in public health genetics. Health Education and Behavior 2005, 32(5):583-588.
80. Koch L., Nordahl-Svendsen M. Providing solutions-defining problems: the imperative of disease prevention in genetic counselling. Social Science and Medicine 2005, 60:823-832.
81. Ludvigsson J., Gustafsson-Stolt U., Liss P.E., Svensson T. Mothers of children in ABIS, a population-based screening for prediabetes, experience few ethical conflicts and have a positive attitude. Annals New York Academy of Science 2002, 958:376-381.
82. Marteau T.M., Lerman C. Genetic risk and behavioural change. British Medical Journal 2001, 322:1056-1059.
83. Marteau T.M., Kinmonth A.L. Screening for cardiovascular risk: public health imperative or matter for individual informed choice?. British Medical Journal 2002, 325:78-80.
84. Marteau T.M., Weinman J. Self-regulation and the behavioural response to DNA risk information: a theoretical analysis and framework for future research. Social Science and Medicine 2006, 62:1360-1368.
85. Morren M., Rijken M., Baanders A.N., Bensing J. Perceived genetic knowledge, attitudes towards genetic testing, and the relationship between these among patients with chronic disease. Patient Education and Counseling 2007, 65(2):197-204.
86. Nelkin D., Andrews L. DNA-identification and surveillance creep. Sociology of Health and Illness 1999, 21(5):689-706.
87. Nordahl Svendsen M., Koch L. Genetics and prevention: a policy in the making. New Genetics and Society 2006, 25(1):51-68.
88. O'Rahilly S., Wareham N.J. Genetic variants and common diseases. Better late than never. New England Journal of Medicine 2006, 355(3):306-308.
89. Peterson S.K. The role of the family in genetic testing: theoretical perspectives, current knowledge, and future directions. Health Education and Behavior 2005, 32(5):627-639.
90. Rabino I. Genetic testing and its implications: human genetics researchers grapple with ethical issues. Science, Technology and Human Values 2003, 28(3):365-402.
91. Rothstein M.A., Boehl H.F. Privacy issues in public health genomics. Genomics and Public Health. Legal and Socio-Ethical Perspectives 2007, 149-162. Martinus Nijhoff, Leiden. B.M. Knoppers (Ed.).
92. Saukko P. Genomic susceptibility-testing and pregnancy: something old, something new. New Genetics and Society 2004, 23(3):313-324.
93. Senior V., Marteau T.M., Peters T.J. Will genetic testing for predisposition for disease result in fatalism? A qualitative study of parent responses to neonatal screening for familial hypercholesterolaemia. Social Science and Medicine 1999, 48:1857-1860.
94. Sladek R., et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445:881-885.
95. Willis E. Public health and the 'new' genetics: balancing individual and collective outcomes. Critical Public Health 2002, 12(2):139-151.
96. Hallowell N. Doing the right thing: genetic risk and responsibility. Sociology of Health and Illness 1999, 21(5):597-621.
97. Hellsten S.K. Biotechnology, genetic information, and community. Genetic Information: Acquisition, Access, and Control 1999, 297-308. Kluwer, New York. A.K. Thompson, R.F. Chadwick (Eds.).
98. Kerr A., Franklin S. Genetic ambivalence: expertise, uncertainty and communication in the context of new genetic technologies. New Technologies in Health Care. Challenge, Change and Innovation 2006, 40-53. Palgrave Macmillan, Basingstoke. A. Webster (Ed.).
99. Khoury M.J., Davis R., Gwinn M., Lindegren M.L., Yoon P. Do we need genomic research for the prevention of common diseases with environmental causes?. American Journal of Epidemiology 2005, 161:799-805.
100. The Health Council of the Netherlands Health Significance of Nanotechnologies 2006, The Health Council of the Netherlands, The Hague.
101. KWF Kankerbestrijding Biomarkers en kankerbestrijding 2007, Gebruik van biomarkers bij erfelijkheidsonderzoek, diagnostiek en behandeling, Amsterdam.
102. Sanderson S.C., Wardle J., Jarvis M., Humphries S.E. Public interest in genetic testing for susceptibility to heart disease and cancer: a population-based survey in the UK. Preventive Medicine 2004, 39:458-464.
103. Shostak S. Locating gene-environment interaction: at the intersections of genetics and public health. Social Science and Medicine 2003, 56:2327-2342.
104. Weiner K., Martin P. A genetic future for coronary heart disease?. Sociology of Health and Illness 2008, 30(3):380-395.
105. Justman M., Bezold C., Rowley W.R. Genomics and society: four scenarios for 2015. Foresight 2002, 4(4):29-35.
106. Knoppers B.M., Chadwick R. Human genetics research: emerging trends in ethics. Nature Review Genetics 2005, 6:75-79.